Innoviva, Inc. (INVA) Q3 2025 10-Q Quarterly Report
Innoviva, Inc. (INVA) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Innoviva, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New operational risk: FDA Priority Review of zoliflodacin with PDUFA date Dec 15, 2025, no advisory committee meeting planned (triggered by NDA acceptance in June 2025)
- • Most materially updated financial risk: Convertible noteholders converted $192.5M principal to 11.1M shares in Aug 2025, reducing debt and interest expense
- • Most impactful regulatory risk: La Jolla Royalty Agreement caps royalty payments to HCR at $225M through Jan 2031 or sales thresholds, impacting future royalties
- • Competitive/market risk: Increased net product sales by 70% Q3 2025 vs Q3 2024 driven by commercial launch of XACDURO® and strategic commercialization efforts
- • Financial liquidity risk: $476.5M cash and equivalents as of Sept 30, 2025, sufficient for 12+ months of operations including share repurchase program up to $125M authorized
Get deeper insights on Innoviva, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.